115 related articles for article (PubMed ID: 38849938)
1. Dual depletion of myeloid-derived suppressor cells and tumor cells with self-assembled gemcitabine-celecoxib nano-twin drug for cancer chemoimmunotherapy.
Zhang X; Liang Q; Cao Y; Yang T; An M; Liu Z; Yang J; Liu Y
J Nanobiotechnology; 2024 Jun; 22(1):319. PubMed ID: 38849938
[TBL] [Abstract][Full Text] [Related]
2. Targeting myeloid-derived suppressor cells in combination with primary mammary tumor resection reduces metastatic growth in the lungs.
Bosiljcic M; Cederberg RA; Hamilton MJ; LePard NE; Harbourne BT; Collier JL; Halvorsen EC; Shi R; Franks SE; Kim AY; Banáth JP; Hamer M; Rossi FM; Bennewith KL
Breast Cancer Res; 2019 Sep; 21(1):103. PubMed ID: 31488209
[TBL] [Abstract][Full Text] [Related]
3. Gemcitabine nanoparticles promote antitumor immunity against melanoma.
Zhang Y; Bush X; Yan B; Chen JA
Biomaterials; 2019 Jan; 189():48-59. PubMed ID: 30388589
[TBL] [Abstract][Full Text] [Related]
4. Gemcitabine directly inhibits myeloid derived suppressor cells in BALB/c mice bearing 4T1 mammary carcinoma and augments expansion of T cells from tumor-bearing mice.
Le HK; Graham L; Cha E; Morales JK; Manjili MH; Bear HD
Int Immunopharmacol; 2009 Jul; 9(7-8):900-9. PubMed ID: 19336265
[TBL] [Abstract][Full Text] [Related]
5. Gemcitabine selectively eliminates splenic Gr-1+/CD11b+ myeloid suppressor cells in tumor-bearing animals and enhances antitumor immune activity.
Suzuki E; Kapoor V; Jassar AS; Kaiser LR; Albelda SM
Clin Cancer Res; 2005 Sep; 11(18):6713-21. PubMed ID: 16166452
[TBL] [Abstract][Full Text] [Related]
6. Targeting the crosstalk between cytokine-induced killer cells and myeloid-derived suppressor cells in hepatocellular carcinoma.
Yu SJ; Ma C; Heinrich B; Brown ZJ; Sandhu M; Zhang Q; Fu Q; Agdashian D; Rosato U; Korangy F; Greten TF
J Hepatol; 2019 Mar; 70(3):449-457. PubMed ID: 30414862
[TBL] [Abstract][Full Text] [Related]
7. Tumor Microenvironment following Gemcitabine Treatment Favors Differentiation of Immunosuppressive Ly6C
Wu C; Tan X; Hu X; Zhou M; Yan J; Ding C
J Immunol; 2020 Jan; 204(1):212-223. PubMed ID: 31776206
[TBL] [Abstract][Full Text] [Related]
8. Targeting myeloid-derived suppressor cells with gemcitabine to enhance efficacy of adoptive cell therapy in bladder cancer.
Bazargan S; Bunch B; Ojwang' AME; Blauvelt J; Landin A; Ali J; Abrahams D; Cox C; Hall AM; Beatty MS; Poch M; Rejniak KA; Pilon-Thomas S
Front Immunol; 2023; 14():1275375. PubMed ID: 37901214
[TBL] [Abstract][Full Text] [Related]
9. Progression of Large Lymphoma Is Significantly Impeded with a Combination of Gemcitabine Chemotherapy and Dendritic Cells Intra-Tumor Vaccination.
Zhu XJ; Yang ZF; Zhou JY; Liu L; Sun XM; Fan ZF; Hu SY; Chen YC; Li WX; Cao M; Wang LX
PLoS One; 2015; 10(7):e0132799. PubMed ID: 26181041
[TBL] [Abstract][Full Text] [Related]
10. Precise engineering of hybrid molecules-loaded macromolecular nanoparticles shows
Liu D; Zhang W; Liu X; Qiu R
Drug Deliv; 2021 Dec; 28(1):776-786. PubMed ID: 33866910
[TBL] [Abstract][Full Text] [Related]
11. Oxaliplatin regulates myeloid-derived suppressor cell-mediated immunosuppression via downregulation of nuclear factor-κB signaling.
Kim NR; Kim YJ
Cancer Med; 2019 Jan; 8(1):276-288. PubMed ID: 30592157
[TBL] [Abstract][Full Text] [Related]
12. Chemo-immunotherapy improves long-term survival in a preclinical model of MMR-D-related cancer.
Maletzki C; Wiegele L; Nassar I; Stenzel J; Junghanss C
J Immunother Cancer; 2019 Jan; 7(1):8. PubMed ID: 30630527
[TBL] [Abstract][Full Text] [Related]
13. Therapeutic targeting with DABIL-4 depletes myeloid suppressor cells in 4T1 triple-negative breast cancer model.
Parveen S; Siddharth S; Cheung LS; Kumar A; Shen J; Murphy JR; Sharma D; Bishai WR
Mol Oncol; 2021 May; 15(5):1330-1344. PubMed ID: 33682324
[TBL] [Abstract][Full Text] [Related]
14. Co-administration of sulforaphane and doxorubicin attenuates breast cancer growth by preventing the accumulation of myeloid-derived suppressor cells.
Rong Y; Huang L; Yi K; Chen H; Liu S; Zhang W; Yuan C; Song X; Wang F
Cancer Lett; 2020 Nov; 493():189-196. PubMed ID: 32891712
[TBL] [Abstract][Full Text] [Related]
15. Therapeutic Tumor Control of HER2 DNA Vaccines Is Achieved by an Alteration of Tumor Cells and Tumor Microenvironment by Gemcitabine and Anti-Gr-1 Ab Treatment in a HER2-Expressing Tumor Model.
Danishmalik SN; Sin JI
DNA Cell Biol; 2017 Sep; 36(9):801-811. PubMed ID: 28777668
[TBL] [Abstract][Full Text] [Related]
16. Oncolytic virus-mediated reducing of myeloid-derived suppressor cells enhances the efficacy of PD-L1 blockade in gemcitabine-resistant pancreatic cancer.
Kajiwara Y; Tazawa H; Yamada M; Kanaya N; Fushimi T; Kikuchi S; Kuroda S; Ohara T; Noma K; Yoshida R; Umeda Y; Urata Y; Kagawa S; Fujiwara T
Cancer Immunol Immunother; 2023 May; 72(5):1285-1300. PubMed ID: 36436021
[TBL] [Abstract][Full Text] [Related]
17. Enhanced anti-tumor efficiency of gemcitabine prodrug by FAPα-mediated activation.
Sun J; Yang D; Cui SH; Zhang HT; Fu Y; Wang JC; Zhang Q
Int J Pharm; 2019 Mar; 559():48-57. PubMed ID: 30677483
[TBL] [Abstract][Full Text] [Related]
18. Combination of thermally ablative focused ultrasound with gemcitabine controls breast cancer via adaptive immunity.
Sheybani ND; Witter AR; Thim EA; Yagita H; Bullock TNJ; Price RJ
J Immunother Cancer; 2020 Aug; 8(2):. PubMed ID: 32819975
[TBL] [Abstract][Full Text] [Related]
19. Chemotherapy-triggered cathepsin B release in myeloid-derived suppressor cells activates the Nlrp3 inflammasome and promotes tumor growth.
Bruchard M; Mignot G; Derangère V; Chalmin F; Chevriaux A; Végran F; Boireau W; Simon B; Ryffel B; Connat JL; Kanellopoulos J; Martin F; Rébé C; Apetoh L; Ghiringhelli F
Nat Med; 2013 Jan; 19(1):57-64. PubMed ID: 23202296
[TBL] [Abstract][Full Text] [Related]
20. Suppressive role of myeloid-derived suppressor cells (MDSCs) in the microenvironment of breast cancer and targeted immunotherapies.
Shou D; Wen L; Song Z; Yin J; Sun Q; Gong W
Oncotarget; 2016 Sep; 7(39):64505-64511. PubMed ID: 27542274
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
